达格列净对射血分数保留心衰患者右室-肺动脉耦联的影响
该研究为CAMEO-DAPA随机临床试验的二次分析,纳入37例血流动力学确诊的HFpEF患者,比较达格列净与安慰剂治疗24周对运动时肺血管负荷及右室-肺动脉耦联的影响。结果显示达格列净改善运动时肺动脉顺应性、降低弹性并增强右室功能,且这些改善与右房压和PCWP下降相关。
要点
- 达格列净治疗24周可改善HFpEF患者运动时的肺动脉顺应性和右室-肺动脉耦联。
- 休息时肺血管负荷和右室-肺动脉交互无显著变化。
- 肺血管和右室功能的改善与PCWP和右房压下降相关。
核心结论
- 达格列净治疗24周可降低HFpEF患者运动时搏动性肺血管负荷并增强动态右室-肺动脉交互,这些改善与PCWP下降幅度相关。
研究设计与样本
- CAMEO-DAPA随机临床试验的二次分析,单中心研究,纳入37例血流动力学确诊HFpEF且运动PCWP≥25 mm Hg的患者,随机接受达格列净或安慰剂治疗24周。
主要发现
- 休息时达格列净对肺动脉负荷或右室-肺动脉交互无影响。
- 运动时右室功能改善,肺动脉搏动指数增加(0.33;95%CI 0.08-0.59;P=0.01),右室s'与肺动脉压比值增加(0.09 cm·s-1/mm Hg;95%CI 0.02-0.16;P=0.01)。
临床怎么用
- 对于HFpEF患者,达格列净可能通过改善运动时右室-肺动脉耦联和肺血管负荷带来获益,尤其适用于运动耐量受限者。
局限性
- 本研究为单中心二次分析,样本量较小(37例),结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Increases in pulmonary capillary wedge pressure (PCWP) during exercise reduce pulmonary artery (PA) compliance, increase pulsatile right ventricular (RV) afterload, and impair RV-PA coupling in patients with heart failure with preserved ejection fraction (HFpEF). The effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on pulmonary vascular properties and RV-PA coupling are unknown. OBJECTIVE: To test the effect of dapagliflozin on right ventricular performance and pulmonary vascular load during exertion in HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA) randomized clinical trial demonstrated improvement in PCWP at rest and exercise over 24 weeks with dapagliflozin compared with placebo with participants recruited between February 2021 and May 2022. This secondary analysis evaluates the effects of dapagliflozin on pulsatile pulmonary vascular load and RV-PA coupling using simultaneous echocardiography and high-fidelity invasive hemodynamic testing with exercise. This was a single-center study including patients with hemodynamically confirmed HFpEF with exercise PCWP of 25 mm Hg or greater. INTERVENTIONS: Dapagliflozin or placebo for 24 weeks. MAIN OUTCOMES AND MEASURES: Pulsatile pulmonary vascular load (PA compliance and elastance) and right ventricular performance (PA pulsatility index, RV systolic velocity [s']/PA mean) during rest and exercise. RESULTS: Among 37 randomized participants (mean [SD] age, 67.4 [8.5] years; 25 female [65%]; mean [SD] body mass index, 34.9 [6.7]; calculated as weight in kilograms divided by height in meters squared), there was no effect of dapagliflozin on PA loading or RV-PA interaction at rest. However, with exercise, dapagliflozin improved PA compliance (placebo-corrected mean difference, 0.57 mL/mm Hg; 95% CI, 0.11-1.03 mL/mm Hg; P = .02) and decreased PA elastance (stiffness; -0.17 mm Hg/mL; 95% CI, -0.28 to -0.07 mm Hg/mL; P = .001). RV function during exercise improved, with increase in PA pulsatility index (0.33; 95% CI, 0.08-0.59; P = .01) and increase in exercise RV s' indexed to PA pressure (0.09 cm·s-1/mm Hg; 95% CI, 0.02-0.16 cm·s-1/mm Hg; P = .01). Improvements in pulsatile RV load and RV-PA coupling were correlated with reduction in right atrial (RA) pressure (PA elastance Pearson r = 0.55; P =.008; RV s'/PA elastance Pearson r = -0.60; P =.002) and PCWP (PA elastance Pearson r = 0.58; P <.001; RV s'/PA elastance Pearson r = -0.47; P = .02). Dapagliflozin increased resistance-compliance time (dapagliflozin, median [IQR] change, 0.06 [0.03-0.15] seconds; placebo, median [IQR] change, 0.01 [-0.02 to 0.05] seconds; P =.046), resulting in higher PA compliance for any exercise pulmonary vascular resistance. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that treatment with dapagliflozin for 24 weeks reduced pulsatile pulmonary vascular load and enhanced dynamic RV-PA interaction during exercise in patients with HFpEF, findings that are related to the magnitude of PCWP reduction. Benefits on dynamic right ventricular-pulmonary vascular coupling may partially explain the benefits of SGLT2 inhibitors in HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04730947.
引用
- Reddy, Carter, Sorimachi, et al. Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 39046727. doi:10.1001/jamacardio.2024.1914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。